While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the biotech is thinking it will pocket $400 million rather than split U.S. profits with its partner Takeda. | While ...
NEWARK, CA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended ...
This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of ...
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
Protagonist Therapeutics has shared a closer look at midphase data on its Johnson & Johnson-partnered oral peptide psoriasis drug candidate. The efficacy fell short of the high bar set by injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results